[EN] 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS<br/>[FR] DÉRIVÉS D'ACIDE PROPANOÏQUE 3-(2,3-DIHYDRO-1H-INDEN-5-YL) ET LEUR UTILISATION EN TANT QUE RÉGULATEURS DE NRF2
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2018104766A1
公开(公告)日:2018-06-14
The present invention relates to compounds of Formula (I), and Formula (II), wherein B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH2)2-triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from -C1-3 alkyl, -O-C1-3 alkyl, CN, - (CH2)2-O-(CH2)2-OR4 and halo; and D is -C(O)OH, -C(O)NHSO2CH3, -SO2NHC(O)CH3, 5-(trifluoromethyl)-4H-1,2,4-triazol-2-yl, or tetrazolyl; and their use as NRF2 regulators.
[EN] SERINE/THREONINE PAK1 INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE PAK1
申请人:HOFFMANN LA ROCHE
公开号:WO2013026914A1
公开(公告)日:2013-02-28
Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
申请人:Diaz Caroline Jean
公开号:US20100222345A1
公开(公告)日:2010-09-02
This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
N-Heterocyclic Carbene-Catalyzed Enantioselective β-Amination of α-Bromoenals Enabled by a Proton-Shuttling Strategy
作者:Ming Lang、Jian Wang
DOI:10.1002/ejoc.201800648
日期:2018.6.22
An enantioselective NHC‐catalyzed β‐amination of α‐bromoenals has been established. This [4+3] annulation protocol allows the rapid assembly of 1,5‐benzodiazepine pharmacophores from simple and readily available starting materials under mild conditions.
CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
申请人:Liu Qingjie
公开号:US20100160303A1
公开(公告)日:2010-06-24
Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof,
are useful as kinase modulators, including Btk modulation.